Market Place
Sourcing Support
Former PhaseBio investor finds US buyer for its PhIII drug to reverse Brilinta
11 May 2023 //
ENDPTS
Bankrupt PhaseBio settles with investor-partner, handing off late-stage drug
18 Jan 2023 //
ENDPTS
SFJ Pharma Announces Closing of Transfer of Bentracimab Assets from PhaseBio
17 Jan 2023 //
BUSINESSWIRE
PhaseBio Plans for Near-Term Sale Using Structured Process
24 Oct 2022 //
BUSINESSWIRE
SFJ plays hardball, demands rights to PhaseBio`s lead candidate
28 Sep 2022 //
ENDPTS
PhaseBio Pharmaceuticals Reports Second Quarter 2022 Financial Results
12 Aug 2022 //
BUSINESSWIRE
PhaseBio Pharmaceuticals Reports First Quarter 2022 Financial Results
16 May 2022 //
BUSINESSWIRE
PhaseBio Announces Successful Pre-BLA Meeting with U.S. FDA for Bentracimab
16 May 2022 //
BUSINESSWIRE
PhaseBio Pharma to Participate in 21st Annual Needham Healthcare Conference
07 Apr 2022 //
BUSINESSWIRE
PhaseBio Announces Positive Results from Phase 2b Trial for Bentracimab
04 Apr 2022 //
BUSINESSWIRE
PhaseBio Reports Fourth Quarter and Full-Year 2021 Financial Results
24 Mar 2022 //
BUSINESSWIRE
PhaseBio Pharmaceuticals Announces Bentracimab Manufacturing Update
08 Mar 2022 //
BUSINESSWIRE
PhaseBio to Participate in Cowen 42nd Annual Conference
24 Feb 2022 //
BUSINESSWIRE
PhaseBio Announces Bentracimab Phase 2b Trial Data
10 Feb 2022 //
BUSINESSWIRE
PhaseBio suspends Phase IIb pulmonary arterial hypertension therapy trial
22 Dec 2021 //
CLINICALTRIALSARENA
PhaseBio blames COVID-19 disruption as heart study axed
22 Dec 2021 //
FIERCEBIOTECH
PhaseBio Publishes Interim Results from Phase 3 Trial of Bentracimab
01 Dec 2021 //
BUSINESSWIRE
PhaseBio Names Jonathan Birchall as Chief Commercial Officer
18 Nov 2021 //
BUSINESSWIRE
PhaseBio Announces Interim Results from Pivotal REVERSE-IT Phase 3
15 Nov 2021 //
BUSINESSWIRE
PhaseBio to Host Investor Call to Discuss Interim Results REVERSE-IT Ph3 Trial
10 Nov 2021 //
BUSINESSWIRE
PhaseBio Reports Q3 2021 Financial Results and Recent Business Highlights
10 Nov 2021 //
BUSINESSWIRE
PhaseBio`s Brilinta reversal agent wins midstage test
03 Nov 2021 //
FIERCEBIOTECH
PhaseBio claims positive PhII in platelet inhibition reversal; Trial software
03 Nov 2021 //
ENDPTS
PhaseBio Announces Interim Analysis of REVERSE-IT Phase 3 Trial
06 Oct 2021 //
BUSINESSWIRE
PhaseBio Appoints William D. Humphries to Board of Directors
15 Sep 2021 //
BUSINESSWIRE
PhaseBio to Present at 23rd Annual H.C. Wainwright Global Investment Conference
31 Aug 2021 //
BUSINESSWIRE
PhaseBio Achieves Milestones Supporting Analysis of REVERSE-IT Phase 3 Trial
12 Aug 2021 //
BUSINESSWIRE
PhaseBio Reports Second-Quarter 2021 Financial Results and Business Highlights
12 Aug 2021 //
BUSINESSWIRE
PhaseBio and SFJ Announce Approval of IND Application in China for Bentracimab
10 Aug 2021 //
BUSINESSWIRE
PhaseBio Pharmaceuticals to Present at the William Blair Biotech
30 Jun 2021 //
BUSINESSWIRE
PhaseBio Announces European Licensing Agreement with Alfasigma S.p.A
17 Jun 2021 //
BUSINESSWIRE
PhaseBio Announces European Licensing Agreement with Alfasigma S.p.A
16 Jun 2021 //
BUSINESSWIRE
PhaseBio Highlights Real-World Healthcare Cost Data Featured at ISPOR 2021
20 May 2021 //
BUSINESSWIRE
PhaseBio Highlights Real-World Bleeding and Surgery Data Featured
17 May 2021 //
BUSINESSWIRE
PhaseBio Announces Proposed Public Offering of Common Stock
17 Mar 2021 //
BUSINESSWIRE
PhaseBio taps a manufacturing partner for Brilinta-reversing med
11 Mar 2021 //
FIERCEBIOTECH
PhaseBio and BioVectra Enter into Supply Agreement to Support DevP Bentracimab
11 Mar 2021 //
BUSINESSWIRE
PhaseBio and BioVectra Enter into Supply Agreement t Bentracimab
10 Mar 2021 //
BUSINESSWIRE
PhaseBio Pharmaceuticals to Participate in Upcoming Investor Conferences
26 Feb 2021 //
BUSINESSWIRE
Phase Genomics to Develop Commercial Platform for the Discovery
23 Feb 2021 //
BUSINATSSWIRE
PhaseBio begins dosing in Phase III trial of bentracimab in EU
29 Jan 2021 //
CLINICALTRIALSARENA
PhaseBio Presents Data from Ph 1b/2a Trial of Pemziviptadil for the Treatment
28 Jan 2021 //
BUSINESSWIRE
PhaseBio Announces Dosing of First Patient in European Union as Part l Ph3
28 Jan 2021 //
BUSINESSWIRE
PhaseBio Provides Pemziviptadil (PB1046) Program Update
23 Oct 2020 //
PRESS RELEASE
PhaseBio Doses First Patients as Part of the REVERSE-IT Trial of Bentracimab
06 Oct 2020 //
BUSINESSWIRE
COVID-19 therapeutics tracker
02 Oct 2020 //
RAPS
PhaseBio Doses First Patient in VANGARD Ph 2 Clinical Trial to Evaluate PB1046
16 Jul 2020 //
BUSINESSWIRE
PhaseBio Launches Clinical Trial to Evaluate PB1046
27 May 2020 //
BUSINESSWIRE
PhaseBio Announces Case Study Highlighting PB1046 Hemodynamic Data
04 Feb 2020 //
GLOBENEWSWIRE
PhaseBio touts ‘breakthrough’ badge bloodthinner reversal agent licensed from AZ
09 Apr 2019 //
ENDPTS
